Eli Lilly presented new four-year data for EBGLYSS in moderate to severe atopic dermatitis. The open-label study shows sustained skin clearance, lasting relief from itching, and a safety profile considered favorable over time. This publication strengthens EBGLYSS’s commercial potential beyond the obesity theme alone and supports the group’s investment case. In a still mixed market backdrop for the stock, this clinical progress could improve investor sentiment in the short term.

Eli Lilly reports promising results with its oral GLP-1 candidate, orforglipron, showing superior blood sugar and weight reductions in type 2 diabetics compared to competitors. The company has filed regulatory applications in over 40 countries, with U.S. approval expected in Q2 2026, including an obesity indication. Additionally, Eli Lilly and Incyte received a positive EMA opinion for Olumiant targeting adolescents with severe alopecia areata, strengthening their portfolio. These advancements enhance the medium-term growth outlook and may support a positive stock momentum.

Eli Lilly reported positive results from its Phase 3b TOGETHER-PsO trial combining Taltz and Zepbound. The study showed significant efficacy in treating both psoriasis and obesity, with 27.1% of patients achieving complete skin clearance. Additionally, the company is expanding its portfolio by acquiring rights to develop clazakizumab, a promising monoclonal antibody. These developments bolster confidence in Lilly's growth prospects on the NYSE.